
    
      This study is designed as a single arm Phase II clinical trial in patients with myelofibrosis
      who are eligible for transplantation from a related donor or from an unrelated donor source.
      Patients will be accrued into two separate strata defined by donor type. Each of the two
      strata will be analyzed separately.

      Patients will be followed yearly from time of enrollment into the study to assess clinical
      response and overall, progression and event free survival, as well as incidence and degree of
      acute and chronic GVHD. We will estimate cumulative survival and transplant related mortality
      in patients enrolled in each of the two strata.
    
  